Esperion Theraptc (ESPR) Stock Price, Quote & News

Company Profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovasc...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 734 887 3903

Website: www.esperion.com

Address:

3891 Ranchero Drive, Suite 150, Ann Arbor, United States

Starlight12 Aug. 4 at 9:56 PM

$ESPR so many other bs stocks go up 300%, 400%, 500% randomly ON BS EARNINGS, RANDOM NEWS But not us-- FKG MMS, TUTES HAVE US PINNED DOWN. FKG MMS, TUTES

0 · Reply

Canyonfundstrader2007 Aug. 4 at 9:44 PM

$ESPR Are they just blood suckers, collecting a salary, or are they really spreading awareness for NEXLIZET & NEXLETOL.

0 · Reply

Albertowest Aug. 4 at 9:24 PM

$ESPR another bites the dust, they are multiplying by the minute this fakes

2 · Reply

newTrader9999 Aug. 4 at 9:21 PM

$ESPR will it ever go to 2 bucks in next one year just so i can break even and move on .... pleaseee

0 · Reply

Marks6972 Aug. 4 at 8:53 PM

$ESPR I saw that. Delta was at 23%. 23% chance we are above 2 in just a few days!!

0 · Reply

djohnson591 Aug. 4 at 8:36 PM

$ESPR Where's SoGen? He was probably told to fall on his sword by his market maker handler. I knew this D-bag was bought and paid for when he started asking me detailed questions about my position and why I'm invested here. Wasn't he saying BK within months? The "Financial Guru". Can't wait for this thing to explode higher. I may unblock him to post some choice words, similar to what he has done over the months.

2 · Reply

Gary9912 Aug. 4 at 8:35 PM

$ESPR Spread the word Esperion.

0 · Reply

MrPeter Aug. 4 at 8:35 PM

$ESPR didn’t realize the Aug $2 were busy today.

0 · Reply

Skipper777 Aug. 4 at 8:15 PM

$ESPR Sleep well friends!

1 · Reply

Starlight12 Aug. 4 at 8:11 PM

$ESPR FKG MMS, TUTES-- IF WE FINISHED 1.55 WE WILL BE BIG GREEN TOMORROW BUT THEY CLOSED US 1.49, SI FKG MMS TUTES HAVE PLANS TO DROP US TO 1.20 IF IM WRONG TOMORROW AND WE GO PAST $2.25 I PROMISE TO POST "I LOVE MMS, TUTES" ONLY FOR 1 DAY BUT 99% WE KNOW FKG TUTES GOING TO KILL RETAIL BLOOD TOMORROW.

0 · Reply

Esperion to Report Second Quarter 2025 Financial Results on August 5

Jul 1, 2025, 8:06 AM EDT - 4 weeks ago

Esperion Appoints Craig Thompson to Board of Directors

Jun 14, 2025, 7:03 AM EDT - 7 weeks ago

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?

May 12, 2025, 8:00 AM EDT - 3 months ago

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

May 9, 2025, 8:00 AM EDT - 3 months ago

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

May 8, 2025, 4:30 PM EDT - 3 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 8, 2025, 6:30 AM EDT - 3 months ago

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

May 6, 2025, 10:49 AM EDT - 3 months ago

Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript

Apr 25, 2025, 8:00 AM EDT - 3 months ago

Esperion to Participate in The Citizens Life Sciences Conference

Apr 24, 2025, 8:00 AM EDT - 3 months ago

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Apr 10, 2025, 8:00 AM EDT - 4 months ago

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Apr 1, 2025, 8:00 AM EDT - 4 months ago

Esperion Appoints Robert E. Hoffman to Board of Directors

Mar 4, 2025, 10:34 AM EST - 5 months ago

Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 6:00 AM EST - 5 months ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 5 months ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Feb 18, 2025, 8:00 AM EST - 5 months ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Dec 18, 2024, 7:00 AM EST - 8 months ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Dec 14, 2024, 9:00 AM EST - 8 months ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

CRDF UI VOD DE FLNC GASS HII

Dec 13, 2024, 6:00 AM EST - 8 months ago

Esperion Announces $210 Million Convertible Debt Financing

Dec 12, 2024, 8:00 AM EST - 8 months ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Dec 8, 2024, 7:43 AM EST - 8 months ago

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Nov 18, 2024, 10:30 AM EST - 9 months ago

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Nov 13, 2024, 2:08 AM EST - 9 months ago

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Nov 7, 2024, 1:35 PM EST - 9 months ago

Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:00 AM EST - 9 months ago

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 4, 2024, 8:00 AM EST - 9 months ago

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Oct 24, 2024, 8:00 AM EDT - 10 months ago

Esperion to Report Third Quarter 2024 Financial Results on November 7

Sep 25, 2024, 4:30 PM EDT - 11 months ago

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sep 3, 2024, 8:00 AM EDT - 11 months ago

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 9:10 AM EDT - 1 year ago

Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs

Aug 16, 2024, 4:09 AM EDT - 1 year ago

Esperion Therapeutics: Strategically Positioned To Grow

Aug 12, 2024, 9:50 PM EDT - 1 year ago

Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 6:00 AM EDT - 1 year ago

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

Jul 16, 2024, 8:00 AM EDT - 1 year ago

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

May 23, 2024, 9:00 AM EDT - 1 year ago

Esperion to Participate in Upcoming June Investor Conferences

May 20, 2024, 6:00 AM EDT - 1 year ago

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

May 20, 2024, 5:43 AM EDT - 1 year ago

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

May 14, 2024, 8:00 AM EDT - 1 year ago

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®

May 7, 2024, 10:05 AM EDT - 1 year ago

Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Call Transcript

May 7, 2024, 6:00 AM EDT - 1 year ago

Esperion Reports First Quarter 2024 Financial Results

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Esperion to Participate in Upcoming May Investor Conferences

Apr 7, 2024, 2:45 PM EDT - 1 year ago

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Apr 1, 2024, 12:48 PM EDT - 1 year ago

Esperion Therapeutics (ESPR) CEO on Cholesterol Lowering Medications

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

Mar 25, 2024, 4:00 PM EDT - 1 year ago

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

Mar 22, 2024, 6:26 PM EDT - 1 year ago

U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Mar 22, 2024, 3:10 PM EDT - 1 year ago

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Starlight12 Aug. 4 at 9:56 PM

$ESPR so many other bs stocks go up 300%, 400%, 500% randomly ON BS EARNINGS, RANDOM NEWS But not us-- FKG MMS, TUTES HAVE US PINNED DOWN. FKG MMS, TUTES

0 · Reply

Canyonfundstrader2007 Aug. 4 at 9:44 PM

$ESPR Are they just blood suckers, collecting a salary, or are they really spreading awareness for NEXLIZET & NEXLETOL.

0 · Reply

Albertowest Aug. 4 at 9:24 PM

$ESPR another bites the dust, they are multiplying by the minute this fakes

2 · Reply

newTrader9999 Aug. 4 at 9:21 PM

$ESPR will it ever go to 2 bucks in next one year just so i can break even and move on .... pleaseee

0 · Reply

Marks6972 Aug. 4 at 8:53 PM

$ESPR I saw that. Delta was at 23%. 23% chance we are above 2 in just a few days!!

0 · Reply

djohnson591 Aug. 4 at 8:36 PM

2 · Reply

Gary9912 Aug. 4 at 8:35 PM

$ESPR Spread the word Esperion.

0 · Reply

MrPeter Aug. 4 at 8:35 PM

$ESPR didn’t realize the Aug $2 were busy today.

0 · Reply

Skipper777 Aug. 4 at 8:15 PM

$ESPR Sleep well friends!

1 · Reply

Starlight12 Aug. 4 at 8:11 PM

0 · Reply

minnesotafarmcountry Aug. 4 at 8:11 PM

$ESPR OT - ONG, I sold 1000 shares of Palantir at $27 last year 😳😥

1 · Reply

hesso Aug. 4 at 7:57 PM

$ESPR i’m looking forward to some good news.just noticed on my notifications people calling me a fool and blocking.prb sogen and bag holder alts

1 · Reply

djohnson591 Aug. 4 at 7:54 PM

$ESPR Wouldn't be surprised to see an after hours announcement like last time either.

0 · Reply

djohnson591 Aug. 4 at 7:53 PM

$ESPR Would you look at that. Hit $1.52 then started flagging and setting up for tomorrow. $1.52 is the exact number it hit in the last cycle, the day before the "surprise" FDA announcement hit in Dec 2023. It was off to the races after that.

0 · Reply

AxiomX Aug. 4 at 7:32 PM

$ESPR He is prepared ⏳⛓️‍💥🤪😁

0 · Reply

Gregg617 Aug. 4 at 7:03 PM

$ESPR I’m gonna do something unprecedented in here since I’m so confident in tomorrow’s earnings I’m gonna declare green day before it even happens now for those of you have been following me for 4 1/2 years in the Stock know that I’m rarely wrong in my calls

1 · Reply

minnesotafarmcountry Aug. 4 at 7:01 PM

$ESPR What’s with the Hippo sitting on the ask? 😡

1 · Reply

stormyfish Aug. 4 at 6:59 PM

$ESPR Earnings tomorrow morning before the bell. Scripts in England are rapidly rising. Come on Sheldon, bring us the money!!! 🤞🤑

0 · Reply

djohnson591 Aug. 4 at 6:59 PM

$ESPR Although the health care system in the US is terrible, I'm not entirely sure you can blame bad US sales on that factor. There's a much more pressing issue IMO.

2 · Reply

simbha Aug. 4 at 6:56 PM

$ESPR With the European BA sales growing faster than USA tells how corrupt and dumb is health care in USA. Very sad...

1 · Reply

stormyfish Aug. 4 at 6:51 PM

$ESPR Hockey stick chart? ⬇️🏒🤑

0 · Reply

Choovachok Aug. 4 at 6:45 PM

$ESPR BA in England 🚀🚀🚀 3,13 mUSD in May

2 · Reply

Market Cap	277.48M
Revenue (ttm)	332.31M
Net Income (ttm)	-51.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-15.57%
Debt to Equity Ratio	-0.33

Volume	4,429,400
Avg Vol	4,310,450
Day's Range	N/A - N/A
Shares Out	198.20M
Stochastic %K	28%
Beta	0.82
Analysts	Sell
Price Target	$5.79